Noteworthy Stock: Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

On Monday, Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) shares price traded between $2.93 and $3.03 during the last trading session below with -0.33 percent at $2.98. The shares recorded trading volume 574,459 shares as compared to its average volume of 1,068,896 shares. The company has 138.34 million shares outstanding and market value of 412.253M. Over the one year trading period, the stock has a peak price of $5.66 and its down is recorded at $2.58. The short ratio in the stock is 6.91 and the short float is around of 5.90 percent.

Achillion Pharmaceuticals, Inc. (ACHN) recently stated financial results for the 3-months ended March 31, 2018. For the 1^st quarter of 2018, the Company stated a net loss of $20.6M or $0.15 per share, contrast with a net loss of $20.2M or $0.15 per share for the 1^st quarter of 2017. Cash, cash equivalents, marketable securities and interest receivable as of March 31, 2018 were $308.4M. The Company also stated that Joseph Truitt has been named Chief Executive Officer and that Milind Deshpande, Ph.D. will be stepping down.

Over the past several months, Achillion has been focused on expanding its global clinical development program for ACH-4471which includes five Phase 2 studies, three in patients with C3G and two in patients with PNH.  The Company anticipates reporting interim data from these studies during the second half of this year.

1^st Quarter 2018 Results

For the 1^st quarter of 2018, the Company stated a net loss of $20.6M, or $0.15 per share, contrast with a net loss of $20.2M, or $0.15 per share for the 1^st quarter of 2017. Cash, cash equivalents, marketable securities, and interest receivable as of March 31, 2018 were $308.4M.

Research and development expenses were $14.8M in the 1^st quarter of 2018, contrast with $15.5M for the same period of 2017. The decrease was primarily Because of reduced non-cash stock compensation and personnel costs Because of our restructuring in February 2018, which resulted in fewer employees, combined with reduced manufacturing and formulation costs related to ACH-5228. These amounts were partially offset by raised clinical and clinical trial costs related to ACH-4471 and ACH-5228, combined with raised preclinical costs related to ACH-5548.

For the 3-months ended March 31, 2018, general and administrative expenses totaled $5.3M, contrast to $5.7M for the same period in 2017, with the decrease primarily Because of reduced non-cash stock compensation combined with reduced legal and consulting fees.

Non-cash stock compensation expense totaled $2.3M for the 1^st quarter of 2018 as contrast to $3.2M for the 1^st quarter of 2017, and is included in research and development, general and administrative and restructuring expenses.

During the 3-months ended March 31, 2018, we incurred $1.8M of restructuring charges. These charges consist primarily of employee severance payments, continuation of benefits and outplacement services resulting from the implementation of our restructuring plan in February 2018 which reduced employee headcount by about 20 percent.

The company has the institutional ownership of 87.00 percent while the Beta factor was 1.00. The stock’s RSI amounts to 46.37. (ACHN) current ratio was 38.00. Return on equity (ROE) was noted as -25.60 percent. EPS growth ratio for the past five years was 0.50 percent

      

Related Posts :